Economic evaluation of interventions for treatment-resistant depression: A systematic review
暂无分享,去创建一个
[1] R. Tamimi,et al. Econometric Issues in Prospective Economic Evaluations Alongside Clinical Trials: Combining the Nonparametric Bootstrap with Methods that Address Missing Data. , 2022, Epidemiologic reviews.
[2] D. Freeman,et al. Appraisal of patient-level health economic models of severe mental illness: systematic review , 2021, The British Journal of Psychiatry.
[3] S. Pype,et al. Real-World Treatment Patterns, Outcomes, Resource Utilization and Costs in Treatment-Resistant Major Depressive Disorder: PATTERN, a Retrospective Cohort Study in Belgium , 2021, PharmacoEconomics - Open.
[4] W. Brouwer,et al. Instruments to assess quality of life in people with mental health problems: a systematic review and dimension analysis of generic, domain- and disease-specific instruments , 2021, Health and Quality of Life Outcomes.
[5] Reed J. D. Sorensen,et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic , 2021, The Lancet.
[6] J. Swift,et al. The importance of listening to patient preferences when making mental health care decisions , 2021, World psychiatry : official journal of the World Psychiatric Association.
[7] M. Roca,et al. Economic impact of treatment-resistant depression: A retrospective observational study. , 2021, Journal of Affective Disorders.
[8] P. Greenberg,et al. The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers , 2021, PharmacoEconomics.
[9] B. Mickey,et al. Long-term quality of life in treatment-resistant depression after electroconvulsive therapy. , 2021, Journal of affective disorders.
[10] E. Mayo-Wilson,et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.
[11] J. Sheehan,et al. Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression. , 2021, Journal of comparative effectiveness research.
[12] M. Milne-Ives,et al. The Effectiveness of Artificial Intelligence Conversational Agents in Health Care: Systematic Review , 2020, Journal of medical Internet research.
[13] N. Kathirvel. Post COVID-19 pandemic mental health challenges , 2020, Asian Journal of Psychiatry.
[14] S. Saeed,et al. Past Epidemics, Natural Disasters, COVID19, and Mental Health: Learning from History as we Deal with the Present and Prepare for the Future , 2020, Psychiatric Quarterly.
[15] R. McIntyre,et al. Burden of Treatment Resistant Depression (TRD) in patients with major depressive disorder in Ontario using Institute for Clinical Evaluative Sciences (ICES) databases: Economic burden and healthcare resource utilization. , 2020, Journal of affective disorders.
[16] D. Soeteman,et al. Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States. , 2020, Psychiatric services.
[17] M. Baggaley. Value-based healthcare in mental health services , 2020, BJPsych Advances.
[18] M. Herdman,et al. Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines , 2020, The European Journal of Health Economics.
[19] G. Galeazzi,et al. Digital Interventions for Screening and Treating Common Mental Disorders or Symptoms of Common Mental Illness in Adults: Systematic Review and Meta-analysis , 2020, Journal of medical Internet research.
[20] C. Stride,et al. Efficacy and cost-effectiveness of intensive short-term dynamic psychotherapy for treatment resistant depression: 18-Month follow-up of the Halifax depression trial. , 2020, Journal of affective disorders.
[21] W. Hoffmann,et al. Is the whole larger than the sum of its parts? Impact of missing data imputation in economic evaluation conducted alongside randomized controlled trials , 2020, The European Journal of Health Economics.
[22] M. Knapp,et al. Economics and mental health: the current scenario , 2020, World psychiatry : official journal of the World Psychiatric Association.
[23] D. Blumberger,et al. Management of Treatment-Resistant Depression: Challenges and Strategies , 2020, Neuropsychiatric disease and treatment.
[24] K. Lohr,et al. Defining treatment‐resistant depression , 2020, Depression and Anxiety.
[25] P. Coyte,et al. Cost–Utility Analysis of Electroconvulsive Therapy and Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression in Ontario , 2019, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[26] B. Rive,et al. The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study , 2019, BMC Psychiatry.
[27] T. Lynch,et al. Refractory depression – cost-effectiveness of radically open dialectical behaviour therapy: findings of economic evaluation of RefraMED trial , 2019, BJPsych Open.
[28] J. Brophy,et al. A Non-inferiority Framework for Cost-Effectiveness Analysis , 2019, International Journal of Technology Assessment in Health Care.
[29] M. Olfson,et al. Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System. , 2019, Journal of managed care & specialty pharmacy.
[30] J. Wildman,et al. Combining Health and Outcomes Beyond Health in Complex Evaluations of Complex Interventions: Suggestions for Economic Evaluation. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[31] I. Anderson,et al. Cost-effectiveness model for a hypothetical monotherapy vs standard of care in adult patients with treatment-resistant depression , 2019, ClinicoEconomics and outcomes research : CEOR.
[32] F. Clement,et al. Current and Common Definitions of Treatment-Resistant Depression: Findings from a Systematic Review and Qualitative Interviews , 2019, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[33] Stef van Buuren,et al. Combining multiple imputation and bootstrap in the analysis of cost‐effectiveness trial data , 2018, Statistics in medicine.
[34] K. Demyttenaere,et al. The Impact of (the Concept of) Treatment-Resistant Depression: An Opinion Review , 2018, The international journal of neuropsychopharmacology.
[36] I. Anderson,et al. The burden of treatment-resistant depression: A systematic review of the economic and quality of life literature. , 2019, Journal of affective disorders.
[37] Russell Fulmer,et al. Using Psychological Artificial Intelligence (Tess) to Relieve Symptoms of Depression and Anxiety: Randomized Controlled Trial , 2018, JMIR mental health.
[38] T. Lynch,et al. Radically open dialectical behaviour therapy for refractory depression: the RefraMED RCT , 2018, Efficacy and Mechanism Evaluation.
[39] T. Peters,et al. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT. , 2018, Health technology assessment.
[40] K. Zivin,et al. Cost-effectiveness of Electroconvulsive Therapy vs Pharmacotherapy/Psychotherapy for Treatment-Resistant Depression in the United States , 2018, JAMA psychiatry.
[41] Y. Zhao,et al. Cost‐Effectiveness Modeling of Repetitive Transcranial Magnetic Stimulation Compared to Electroconvulsive Therapy for Treatment‐Resistant Depression in Singapore , 2018, Neuromodulation : journal of the International Neuromodulation Society.
[42] Thomas Kohlmann,et al. A Systematic Review of Studies Comparing the Measurement Properties of the Three-Level and Five-Level Versions of the EQ-5D , 2018, PharmacoEconomics.
[43] H. Akil,et al. Treatment resistant depression: A multi-scale, systems biology approach , 2018, Neuroscience & Biobehavioral Reviews.
[44] A. Culyer,et al. Rival perspectives in health technology assessment and other economic evaluations for investing in global and national health. Who decides? Who pays? , 2018, F1000Research.
[45] A. Young,et al. Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom. , 2017, Journal of affective disorders.
[46] Mickaël Hiligsmann,et al. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1/3) , 2016, Expert review of pharmacoeconomics & outcomes research.
[47] T. Trikalinos,et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. , 2016, JAMA.
[48] Richard G. Moore,et al. Efficacy and cost-effectiveness of a specialist depression service versus usual specialist mental health care to manage persistent depression: a randomised controlled trial. , 2016, The lancet. Psychiatry.
[49] T. Peters,et al. Long-term effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: follow-up of the CoBalT randomised controlled trial. , 2016, The lancet. Psychiatry.
[50] H. Ravaghi,et al. Economic evaluation of resistant major depressive disorder treatment in Iranian population: a comparison between repetitive Transcranial Magnetic Stimulation with electroconvulsive , 2016, Medical journal of the Islamic Republic of Iran.
[51] Franziska Wulf,et al. Methods For The Economic Evaluation Of Health Care Programmes , 2016 .
[52] I. Dhalla,et al. Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: An Economic Analysis. , 2016, Ontario health technology assessment series.
[53] K. Nguyen,et al. Cost-Effectiveness of Repetitive Transcranial Magnetic Stimulation versus Antidepressant Therapy for Treatment-Resistant Depression. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[54] S. Riedel-Heller,et al. Cost-Effectiveness of Collaborative Care for the Treatment of Depressive Disorders in Primary Care: A Systematic Review , 2015, PloS one.
[55] R. Willke,et al. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[56] M. Cowie. National Institute for Health and Care Excellence. , 2015, European heart journal.
[57] L. Vallejo-Torres,et al. Cost-effectiveness of electroconvulsive therapy compared to repetitive transcranial magnetic stimulation for treatment-resistant severe depression: a decision model , 2014, Psychological Medicine.
[58] C. Altar,et al. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013. , 2014, Psychiatric services.
[59] S. Paisley,et al. A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. , 2014, Health technology assessment.
[60] T. Peters,et al. Cost-effectiveness of cognitive-behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: economic evaluation of the CoBalT Trial. , 2014, The British journal of psychiatry : the journal of mental science.
[61] A. Serretti,et al. Challenging sequential approach to treatment resistant depression: Cost-utility analysis based on the Sequenced Treatment Alternatives to Relieve Depression (STAR⁎D) trial , 2013, European Neuropsychopharmacology.
[62] S. Edwards,et al. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation. , 2013, Health technology assessment.
[63] N. Olchanski,et al. The economic burden of treatment-resistant depression. , 2013, Clinical therapeutics.
[64] A. Stern,et al. Repetitive transcranial magnetic stimulation for treatment-resistant depression , 2013 .
[65] C. Gudex,et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study , 2012, Quality of Life Research.
[66] Kim Woodbridge-Dodd. Values-based practice in mental health and psychiatry , 2012, Current opinion in psychiatry.
[67] Murray Krahn,et al. Conceptualizing a Model , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[68] J. Birt,et al. Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review , 2012, Cost Effectiveness and Resource Allocation.
[69] C. Carswell. Measuring and Valuing Health Benefits for Economic Valuation , 2007, PharmacoEconomics.
[70] Stavros Petrou,et al. Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting , 2011, BMJ : British Medical Journal.
[71] A. Cleare,et al. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. , 2009, Journal of affective disorders.
[72] William W. McDonald,et al. Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis , 2009, Advances in therapy.
[73] J. Rothwell,et al. Cost-effectiveness of transcranial magnetic stimulation vs. electroconvulsive therapy for severe depression: a multi-centre randomised controlled trial. , 2008, Journal of affective disorders.
[74] M. Knapp,et al. “The trouble with QALYs…” , 2007, Epidemiology and Psychiatric Sciences.
[75] M. Aalabaf-Sabaghi. Decision modelling for health economic evaluation , 2007, Journal of Epidemiology and Community Health.
[76] D. Malone. A Budget-Impact and Cost-Effectiveness Model for Second-Line Treatment of Major Depression , 2007, Journal of managed care pharmacy : JMCP.
[77] J. Rothwell,et al. The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: a multicentre pragmatic randomised controlled trial and economic analysis. , 2007, Health technology assessment.
[78] D. Kupfer,et al. Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report , 2006 .
[79] B. Lebowitz,et al. Medication augmentation after the failure of SSRIs for depression. , 2006, The New England journal of medicine.
[80] M. Posternak,et al. How should remission from depression be defined? The depressed patient's perspective. , 2006, The American journal of psychiatry.
[81] Elisabeth Fenwick,et al. A guide to cost-effectiveness acceptability curves. , 2005, The British journal of psychiatry : the journal of mental science.
[82] H. D. de Vet,et al. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria , 2005, International Journal of Technology Assessment in Health Care.
[83] M. Posternak,et al. Is the Cutoff to Define Remission on the Hamilton Rating Scale for Depression Too High? , 2005, The Journal of nervous and mental disease.
[84] Simon Gilbody,et al. Stepped care in psychological therapies: access, effectiveness and efficiency , 2005, British Journal of Psychiatry.
[85] M Sculpher,et al. Health Technology Assessment: Development and Future , 2009 .
[86] M. George,et al. Decision Analysis of the Cost-Effectiveness of Repetitive Transcranial Magnetic Stimulation Versus Electroconvulsive Therapy for Treatment of Nonpsychotic Severe Depression , 2004, CNS Spectrums.
[87] P. Kind,et al. Usefulness of EQ-5D in Assessing Health Status in Primary Care Patients with Major Depressive Disorder , 2004, Health and quality of life outcomes.
[88] A. Rush,et al. The cost consequences of treatment-resistant depression. , 2004, The Journal of clinical psychiatry.
[89] M. Posternak,et al. Defining remission on the Montgomery-Asberg depression rating scale. , 2004, The Journal of clinical psychiatry.
[90] P. Sullivan,et al. A Comparison of the Direct Costs and Cost Effectiveness of Serotonin Reuptake Inhibitors and Associated Adverse Drug Reactions , 2004, CNS drugs.
[91] Maurizio Fava,et al. Diagnosis and definition of treatment-resistant depression , 2003, Biological Psychiatry.
[92] M. Thase,et al. Research issues in the study of difficult-to-treat depression , 2003, Biological Psychiatry.
[93] S. Palmer,et al. Use of cognitive therapy for relapse prevention in chronic depression , 2003, British Journal of Psychiatry.
[94] T. Gale,et al. Defining remission by cut off score on the MADRS: selecting the optimal value. , 2002, Journal of affective disorders.
[95] M. Boyle,et al. Multiattribute and Single‐Attribute Utility Functions for the Health Utilities Index Mark 3 System , 2002, Medical care.
[96] W. Katon,et al. Cost-effectiveness of a collaborative care program for primary care patients with persistent depression. , 2001, The American journal of psychiatry.
[97] A Briggs,et al. Economic evaluation and clinical trials: size matters , 2000, BMJ : British Medical Journal.
[98] M. Boyle,et al. Cost-utility analysis in depression: the McSad utility measure for depression health states. , 2000, Psychiatric services.
[99] K Claxton,et al. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.
[100] D A Revicki,et al. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. , 1998, Journal of affective disorders.
[101] Michael C. Bailey,et al. Cost-Effective Maintenance Treatment of Resistant Geriatric Depression , 1998 .
[102] S. Wilson. Methods for the economic evaluation of health care programmes , 1987 .